Literature DB >> 9603111

Inhaled nitric oxide versus conventional therapy: effect on oxygenation in ARDS.

J R Michael1, R G Barton, J R Saffle, M Mone, B A Markewitz, K Hillier, M R Elstad, E J Campbell, B E Troyer, R E Whatley, T G Liou, W M Samuelson, H J Carveth, D M Hinson, S E Morris, B L Davis, R W Day.   

Abstract

A randomized, controlled clinical trial was performed with patients with acute respiratory distress syndrome (ARDS) to compare the effect of conventional therapy or inhaled nitric oxide (iNO) on oxygenation. Patients were randomized to either conventional therapy or conventional therapy plus iNO for 72 h. We tested the following hypotheses: (1) that iNO would improve oxygenation during the 72 h after randomization, as compared with conventional therapy; and (2) that iNO would increase the likelihood that patients would improve to the extent that the FI(O2) could be decreased by > or = 0.15 within 72 h after randomization. There were two major findings. First, That iNO as compared with conventional therapy increased Pa(O2)/FI(O2) at 1 h, 12 h, and possibly 24 h. Beyond 24 h, the two groups had an equivalent improvement in Pa(O2)/FI(O2). Second, that patients treated with iNO therapy were no more likely to improve so that they could be managed with a persistent decrease in FI(O2) > or = 0.15 during the 72 h following randomization (11 of 20 patients with iNO versus 9 of 20 patients with conventional therapy, p = 0.55). In patients with severe ARDS, our results indicate that iNO does not lead to a sustained improvement in oxygenation as compared with conventional therapy.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9603111     DOI: 10.1164/ajrccm.157.5.96-10089

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  43 in total

Review 1.  Physiological reactions of nitric oxide and hemoglobin: a radical rethink.

Authors:  S S Gross; P Lane
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-31       Impact factor: 11.205

Review 2.  Inhaled nitric oxide treatment for preterm infants with hypoxic respiratory failure.

Authors:  R L Smyth
Journal:  Thorax       Date:  2000-08       Impact factor: 9.139

Review 3.  Inhaled nitric oxide and pulmonary vasoreactivity.

Authors:  M Aranda; R G Pearl
Journal:  J Clin Monit Comput       Date:  2000       Impact factor: 2.502

4.  Inhaled nitric oxide for ARDS: searching for a more focused use.

Authors:  Luca M Bigatello; Judith Hellman
Journal:  Intensive Care Med       Date:  2003-10       Impact factor: 17.440

5.  Inhaled nitric oxide fraction is influenced by both the site and the mode of administration.

Authors:  E Sieffert; L Ducros; M R Losser; D M Payen
Journal:  J Clin Monit Comput       Date:  1999-12       Impact factor: 2.502

Review 6.  The pulmonary physician in critical care - part 9: non-ventilatory strategies in ARDS.

Authors:  J Cranshaw; M J D Griffiths; T W Evans
Journal:  Thorax       Date:  2002-09       Impact factor: 9.139

7.  [Inhaled nitric oxide for the treatment of ARDS].

Authors:  H Lohbrunner; M Deja; T Busch; C D Spies; R Rossaint; U Kaisers
Journal:  Anaesthesist       Date:  2004-08       Impact factor: 1.041

8.  [Acute respiratory distress syndrome].

Authors:  M Hecker; M A Weigand; K Mayer
Journal:  Internist (Berl)       Date:  2012-05       Impact factor: 0.743

9.  Inhaled nitric oxide therapy in adults: European expert recommendations.

Authors:  Peter Germann; Antonio Braschi; Giorgio Della Rocca; Anh Tuan Dinh-Xuan; Konrad Falke; Claes Frostell; Lars E Gustafsson; Philippe Hervé; Philippe Jolliet; Udo Kaisers; Hector Litvan; Duncan J Macrae; Marco Maggiorini; Nandor Marczin; Bernd Mueller; Didier Payen; Marco Ranucci; Dietmar Schranz; Rainer Zimmermann; Roman Ullrich
Journal:  Intensive Care Med       Date:  2005-06-23       Impact factor: 17.440

10.  S-nitroso human serum albumin given after LPS challenge reduces acute lung injury and prolongs survival in a rat model of endotoxemia.

Authors:  A Jakubowski; N Maksimovich; R Olszanecki; A Gebska; H Gasser; B K Podesser; S Hallström; S Chlopicki
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2008-10-15       Impact factor: 3.000

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.